Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1373)	12/15/2001 8:53:22 AM
From: Icebrg	Respond to of 10345

Bioject Announces Agreement Regarding Elan Stock - PORTLAND, Ore., Dec 14, 2001 /PRNewswire via COMTEX/ -- Bioject Medical Technologies, Inc, (BJCT) , a leading developer of needle-free drug delivery systems, today announced that it has entered into an agreement with affiliates of Elan Corporation plc with respect to various matters previously in dispute regarding Elan's ownership interest in Bioject. Under the terms of the agreement, Elan agreed to eliminate, on a prospective basis from October 2001, the 9% dividend due Elan from its holdings in Bioject's Series A Preferred Stock, to terminate its 350,000 Series K warrants to purchase Bioject common stock and to partially exercise its Series P warrant to purchase 252,666 shares of Bioject common stock. In addition, if certain trading price conditions are met Elan agreed to exercise the remaining 505,334 Series P warrants to purchase common stock over the next two years. Bioject issued to Elan additional shares of Series A Preferred Stock in respect of dividend obligations on the Series A Preferred Stock through October 2001, agreed to eliminate the redemption and mandatory conversion provisions of the Series A and Series C Preferred Stock held by Elan and will withdraw its lawsuit to compel the redemption of the Series A Preferred Stock. Elan also acquired a six-month option to utilize Bioject's proprietary IJECT(TM) technology in connection with a drug compound to be identified. "We are pleased we were able to come to agreement with Elan on satisfactory terms for both parties," said Jim O'Shea, Chairman, President and CEO of Bioject. "We now have a solid foundation to enhance our relationship on a prospective basis. We feel this agreement will be rewarding for Bioject, Elan and our shareholders." About Bioject Medical Technologies: Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical and biotechnology companies. Bioject's partners now include Amgen, Serono and Alkermes.